Thermo Fisher Scientific has enrolled the first patient in its new PPD CorEvitas Alzheimer’s Disease Registry. Developed as an international, multi-country initiative, the registry will generate real-world data under a standard global protocol to support novel evaluations of drug safety and effectiveness, critical for regulators, clinicians, patients, and caregivers.
Its longitudinal design, combined with clinician-reported data from routine practice, will enable a comprehensive understanding of Alzheimer’s therapy outcomes in real-world settings. The registry will highlight long-term safety, treatment patterns, and the evolving use of approved therapies, while helping to identify unmet medical needs, clarify the disease’s impact on patients, and assess the clinical outcomes associated with existing treatments.
Detailed monitoring and assessment of drug safety events are vital to the registry, including MRI-based evaluations of brain bleeding and swelling that could be caused by certain treatments, as well as measure of plaque clearence, an important measure of treatment effectiveness in correlation with cognition outcomes. This data will be utilised to generate a more complete understanding of safety and clinical outcomes in this patient population.
Peter Wahl, vice president and global head of scientific affairs for PPD CorEvitas Clinical Registries, Thermo Fisher Scientific, said, “The launch of this registry reflects the power of collaboration between clinicians, industry partners and scientific leaders to accelerate progress in Alzheimer’s disease research. Together, we are building a regulatory-grade, real-world evidence foundation that will help shape the understanding of current and next generation of therapies.”